Study		Exclusion reasons	Remarks	Reference(s)
O'Brien (Part A: uninfected household contacts), 2021	randomized controlled trial		< Study carried out before the release of the omicron variant >	O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569 O'Brien MP et al. New England Journal of Medicine 10.1056/NEJMoa2109682 O?Brien MP et al. medRxiv 10.1101/2021.06.14.21258567
O'Brien (Part B: recently infected asymptomatic patients), 2021	randomized controlled trial			O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569
CT-P59 1.2, 2020	randomized controlled trial	no clinically relevant endpoint	preliminary unpublished results extracted from the EMA review document. < Study carried out before the release of the omicron variant >
Isa, 2021	randomized controlled trial	other	Phase I: multiple-dose administration of REGEN-COV.	Isa F et al. medRxiv 10.1101/2021.11.10.21265889